Compile Data Set for Download or QSAR
Report error Found 9873 for UniProtKB: P28482
TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204382(US9242996, 461)
Affinity DataIC50: 0.00431nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204241(US9242996, 315)
Affinity DataIC50: 0.00500nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204384(US9242996, 463)
Affinity DataIC50: 0.00550nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204469(US9242996, 179)
Affinity DataIC50: 0.00612nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204281(US9242996, 360)
Affinity DataIC50: 0.00665nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204470(US9242996, 180)
Affinity DataIC50: 0.00671nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204316(US9242996, 395)
Affinity DataIC50: 0.00827nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204294(US9242996, 373)
Affinity DataIC50: 0.00837nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204168(US9242996, 242)
Affinity DataIC50: 0.00875nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204405(US9242996, 478a)
Affinity DataIC50: 0.00900nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204301(US9242996, 380)
Affinity DataIC50: 0.00970nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204270(US9242996, 344)
Affinity DataIC50: 0.00977nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204255(US9242996, 329)
Affinity DataIC50: 0.0100nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1/3(Human)
Wyeth Research

Curated by ChEMBL
LigandPNGBDBM28123(CHEMBL318804 | 4-({3-chloro-4-[(1-methyl-1H-imidaz...)
Affinity DataIC50: 0.0100nMAssay Description:Inhibit ion of MAPK phosphorylation in LoVo cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM50115402(CHEMBL3608588)
Affinity DataIC50: 0.0100nMAssay Description:Inhibition of ERK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/25/2016
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204308(US9242996, 387)
Affinity DataIC50: 0.0100nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204274(US9242996, 353)
Affinity DataIC50: 0.0103nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204496(US9242996, 206)
Affinity DataIC50: 0.0104nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204303(US9242996, 382)
Affinity DataIC50: 0.0107nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204269(US9242996, 343)
Affinity DataIC50: 0.0110nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204471(US9242996, 181)
Affinity DataIC50: 0.0119nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204169(US9242996, 243)
Affinity DataIC50: 0.0121nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204185(US9242996, 259)
Affinity DataIC50: 0.0127nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204479(US9242996, 189)
Affinity DataIC50: 0.0139nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204264(US9242996, 338)
Affinity DataIC50: 0.0139nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204188(US9242996, 262)
Affinity DataIC50: 0.0140nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204278(US9242996, 357)
Affinity DataIC50: 0.0143nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204262(US9242996, 336)
Affinity DataIC50: 0.0143nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204315(US9242996, 394)
Affinity DataIC50: 0.0153nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204193(US9242996, 267)
Affinity DataIC50: 0.0158nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204187(US9242996, 261)
Affinity DataIC50: 0.0168nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204268(US9242996, 342)
Affinity DataIC50: 0.0173nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204272(US9242996, 346)
Affinity DataIC50: 0.0175nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204480(US9242996, 190)
Affinity DataIC50: 0.0176nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204297(US9242996, 376)
Affinity DataIC50: 0.0183nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204386(US9242996, 465)
Affinity DataIC50: 0.0187nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204458(US9242996, 133)
Affinity DataIC50: 0.0187nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM50115401(CHEMBL3608589)
Affinity DataIC50: 0.0190nMAssay Description:Inhibition of ERK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/25/2016
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204275(US9242996, 354)
Affinity DataIC50: 0.0194nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204183(US9242996, 257)
Affinity DataIC50: 0.0197nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204317(US9242996, 396)
Affinity DataIC50: 0.0198nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204166(US9242996, 240)
Affinity DataIC50: 0.0199nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM204335(US9242996, 414)
Affinity DataIC50: 0.0200nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2016
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM365121(US9867833, Compound I-59(R) | 4-(9-(3-fluoro-4- me...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM365119(4-(9-(4-fluorobenzyl)-8,9- dihydro-7H-6-oxa-1,2,2a...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM365071(4-(9-(2-chlorobenzyl)-8,9- dihydro-7H-6-oxa-1,2,2a...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM383280(US10278975, Compound I-55 R | 4-(3-(4-chlorobenzyl...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM383296(4-(3-(4-fluorobenzyl)-3,4- dihydro-5-oxa-1,2,2a1- ...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM383294(4-(9-((4-cyclopropyl-1H- pyrazol-1-yl)methyl)-8,9-...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM383316(9-benzyl-6-methyl-4-(2-((1- methyl-1H-pyrazol-5- y...)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested in an enzymatic assay using human ERK-2 (Mitogen Activated Kinase 1), recombinantly expressed as an n-terminal 6-His fusion pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2020
Entry Details
US Patent

Displayed 1 to 50 (of 9873 total ) | Next | Last >>
Jump to: